Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial ...

Meanwhile, there was consistently less bleeding in the rivaroxaban, apixaban, dabigatran, and edoxaban groups in comparison with those who received warfarin. The large observational study ...